Massive 3,000-Person diabetes drug study launches
NCT ID NCT07023172
Summary
This study is observing how well a diabetes medication called Proline Plus Empagliflozin works in real-world settings for people with type 2 diabetes. Researchers will follow 3,000 patients for up to 48 weeks to see how effectively it controls blood sugar and monitor for any side effects. The study doesn't change normal medical care—doctors prescribe the medication as they normally would, either alone or with other diabetes treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Drum Tower Hospital, Medical School of Nanjing University
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xinyang Central Hospital
RECRUITINGXinyang, Henan, 464000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.